Abstract
IntroductionThe objective of this study was to analyse the susceptibility of Mycoplasma genitalium to macrolides and fluoroquinolones using molecular techniques. MethodsSusceptibility to macrolides was tested (Gipuzkoa, 2014–2017) by a rapid probe-based real-time polymerase chain reaction assay (23S rRNA gene) and to fluoroquinolones by sequencing the parC and gyrA genes. ResultsMutations associated with macrolide resistance were detected in 43/263 (16.3%) cases and potential fluoroquinolone resistance in 21/267 (7.9%). Macrolide resistance was more frequent in patients previously treated with azithromycin (76.5% vs 7.4%, p<0.001) as well as in those treated with a single 1g dose (31.3%) vs the extended regimen (7%, p<0.001). There were 5/245 (2%) cases with mutations probably associated with resistance to both antibiotics. ConclusionsThe technique used for testing M. genitalium susceptibility to azithromycin allowed the rapid implementation of resistance-guided antibiotic therapy. Moxifloxacin could be a good option in cases of macrolide resistance.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
